Your browser doesn't support javascript.
loading
Consensus Statement on Proton Therapy in Mesothelioma.
Zeng, Jing; Badiyan, Shahed N; Garces, Yolanda I; Wong, Tony; Zhang, Xiaodong; Simone, Charles B; Chang, Joe Y; Knopf, Antje C; Mori, Shinichiro; Iwata, Hiromitsu; Meijers, Arturs; Li, Heng; Bues, Martin; Liu, Wei; Schild, Steven E; Rengan, Ramesh.
Afiliação
  • Zeng J; Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington. Electronic address: jzeng13@uw.edu.
  • Badiyan SN; Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.
  • Garces YI; Department of Radiation Oncology, Mayo Clinic Rochester, Rochester, Minnesota.
  • Wong T; Seattle Cancer Care Alliance Proton Therapy Center, Seattle, Washington.
  • Zhang X; Department of Radiation Physics, Division of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Simone CB; New York Proton Center, New York, New York.
  • Chang JY; Department of Radiation Oncology, Division of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Knopf AC; Division of Radiotherapy, University of Groningen, Groningen, Netherlands.
  • Mori S; Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan.
  • Iwata H; Department of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City West Medical Center, Nagoya, Japan.
  • Meijers A; Division of Radiotherapy, University of Groningen, Groningen, Netherlands.
  • Li H; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins Medicine, Baltimore, Maryland.
  • Bues M; Department of Radiation Oncology, Mayo Clinic Arizona, Scottsdale, Arizona.
  • Liu W; Department of Radiation Oncology, Mayo Clinic Arizona, Scottsdale, Arizona.
  • Schild SE; Department of Radiation Oncology, Mayo Clinic Arizona, Scottsdale, Arizona.
  • Rengan R; Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington.
Pract Radiat Oncol ; 11(2): 119-133, 2021.
Article em En | MEDLINE | ID: mdl-32461036
ABSTRACT

PURPOSE:

Radiation therapy for mesothelioma remains challenging, as normal tissue toxicity limits the amount of radiation that can be safely delivered to the pleural surfaces, especially radiation dose to the contralateral lung. The physical properties of proton therapy result in better sparing of normal tissues when treating the pleura, both in the postpneumonectomy setting and the lung-intact setting. Compared with photon radiation, there are dramatic reductions in dose to the contralateral lung, heart, liver, kidneys, and stomach. However, the tissue heterogeneity in the thorax, organ motion, and potential for changing anatomy during the treatment course all present challenges to optimal irradiation with protons.

METHODS:

The clinical data underlying proton therapy in mesothelioma are reviewed here, including indications, advantages, and limitations.

RESULTS:

The Particle Therapy Cooperative Group Thoracic Subcommittee task group provides specific guidelines for the use of proton therapy for mesothelioma.

CONCLUSIONS:

This consensus report can be used to guide clinical practice, insurance approval, and future research.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Terapia com Prótons / Mesotelioma Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Terapia com Prótons / Mesotelioma Idioma: En Ano de publicação: 2021 Tipo de documento: Article